Technical analysis of Arcellx, Inc. (ACLX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM).
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +76.49% |
| 1 year | +50.58% |
| 3 years | +239.54% |
52-Week Range
| 52-week High | $115.13 |
| 52-week Low | $47.86 |
| Avg Volume (90d) | 2.1M |
Technical Indicators
| SMA 50 | $112.63 |
| SMA 200 | $84.18 |
| Beta | 0.25 |
| 30-day Volatility (annualised) | 1.6% |
| Price vs SMA 50 | +2.2% |
| Price vs SMA 200 | +36.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $90.25 | |
| 2025-11 | $72.71 | -19.4% |
| 2025-12 | $65.20 | -10.3% |
| 2026-01 | $68.31 | +4.8% |
| 2026-02 | $113.79 | +66.6% |
| 2026-03 | $114.82 | +0.9% |
| 2026-04 | $115.07 | +0.2% |
| 2026-05 | $115.07 | +0.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
Price
| Price | $115.07 |
| Market Cap | $6.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 16.10 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.24 |
| Current Ratio | 4.44 |